What the clinical evidence shows

The short answer, for patients who are suitable candidates, is that the clinical data are encouraging — though they come with an important qualification worth stating upfront.

In published multi-centre studies of ChondroFiller injection in focal hip cartilage defects and femoroacetabular impingement (FAI), patients reported a mean Harris Hip Score improvement of +33 points. That is a substantial, quantified gain on a validated 100-point functional scale. Alongside those patient-reported results, MOCART MRI regeneration scores of 70–87 have been recorded across ChondroFiller applications, providing structural imaging confirmation that tissue is filling the defect — not merely that symptoms have eased.

More than 19,000 ChondroFiller injections have been performed globally, and five-year-plus outcome durability has been reported in suitable patients. However, the evidence base is most mature in the knee; hip data are present but less voluminous, and that distinction should be factored into any individual assessment.

On the central question of hip replacement delay: the available evidence demonstrates functional score improvement and MRI-confirmed tissue infill, but no randomised controlled trial has yet tracked arthroplasty conversion rates directly as a primary outcome. The biological case for slowing cartilage deterioration is supported by the data shown; a guarantee of avoiding replacement is not.

How the injection works inside the hip joint

Unlike a standard joint injection — where fluid is deposited into the joint cavity and dispersed — a ChondroFiller injection targets the defect itself. Delivered in an outpatient clinic under ultrasound guidance, with local anaesthesia rather than a general anaesthetic, the procedure requires no operating theatre and no incision.

ChondroFiller is an acellular type I/III collagen scaffold manufactured by Meidrix Biomedicals GmbH in Germany. It arrives as a liquid and, once placed into the cartilage lesion under image guidance, gels in situ within minutes. The stabilised scaffold then acts as a biological framework: the patient's own progenitor cells migrate into the matrix and begin laying down new cartilage tissue. This process — matrix-induced chondrogenesis — takes place over roughly 6–12 months, which is why the structural improvement captured on MRI builds progressively after treatment.

The distinction from hyaluronic acid (HA) viscosupplementation is worth making clearly, because patients are often familiar with HA injections. HA is deposited into the joint cavity as a lubricant; it does not enter or fill a cartilage defect and is not designed to be regenerative. Its effects typically last around six months. ChondroFiller occupies a different role: it is placed at the defect surface and is intended to support new tissue formation rather than lubricate the wider joint space. The two treatments are not competing versions of the same thing — they act on different targets by different mechanisms.

Critically, because the approach is additive — laying down a protective scaffold over damaged cartilage rather than cutting or debriding it — the surrounding joint structures remain intact.

Which hip patients are most likely to benefit

The patients who tend to do best with ChondroFiller injection share a consistent clinical profile — and identifying that profile is as useful for ruling people in as it is for ruling them out.

Focal defects, ICRS Grade 3–4. The treatment targets lesions extending deep into cartilage thickness or through the subchondral plate — the tier of damage where conservative measures have run their course but the joint still retains enough structure to support regeneration. Defect size is relevant: ChondroFiller scaffold covers lesions up to 3 cm², with a second box extending coverage to approximately 6 cm² for larger areas.

FAI and sport-related damage in active adults. Femoroacetabular impingement is among the most common causes of focal hip cartilage damage in younger and middle-aged adults. Where FAI has produced a defined cartilage lesion, ChondroFiller injection addresses the defect directly — provided the underlying impingement mechanics have been managed separately.

Surrounding cartilage quality. The scaffold relies on adjacent tissue to support cell migration and integration. Where the surrounding cartilage is reasonably intact, the biological environment is more favourable and outcomes are more predictable; widespread degeneration across the joint reduces that advantage.

At the other end of the spectrum, advanced diffuse osteoarthritis — Kellgren-Lawrence Grade IV with no discrete focal component — falls outside the core indication. Where structural integrity is largely lost across the whole joint surface, cartilage regeneration is not a realistic pathway, and a joint replacement discussion becomes the appropriate next step.

Defect location within the hip and the precise condition of surrounding tissue cannot be assessed from symptoms alone; both require imaging review and a clinical consultation to determine whether ChondroFiller injection is the right course.

Where ChondroFiller injection fits in the hip care pathway

Placing ChondroFiller injection on the care continuum helps clarify what the treatment is designed to do — and what it is not.

The hip care pathway runs through four stages: symptom management (physiotherapy, anti-inflammatories, activity modification); biologic and injection support (such as PRP or hyaluronic acid, which address pain and inflammation without repairing tissue); cartilage scaffold restoration; and, where preservation is no longer viable, joint replacement. ChondroFiller injection sits at Stage 3 — active structural restoration — not at Stage 2 alongside symptom-management injections, and not as a palliative step just before surgery.

For patients with more diffuse wear — particularly Kellgren-Lawrence Grade III/IV osteoarthritis where a focal component coexists with broader joint degeneration — ChondroFiller injection may be combined with Arthrosamid, a polyacrylamide hydrogel. The two work differently: ChondroFiller is the regenerative scaffold, recruiting the patient's own cells to rebuild tissue at the defect site; Arthrosamid is a non-regenerative cushioning hydrogel that integrates into the synovial tissue to provide mechanical support. They are not interchangeable, nor do they fall into the same treatment category.

Where joint mechanics — FAI anatomy or subtle dysplasia — contribute to ongoing cartilage stress, addressing those factors alongside scaffold treatment is likely to support longer-term durability of the repair rather than leave the underlying load unmanaged.

For patients whose scale of damage or clinical profile makes the injectable route unsuitable, surgical restoration procedures such as OATS or MACI remain theatre-based alternatives within the same restoration stage. ChondroFiller injection is the minimally invasive option at Stage 3, not a substitute for a different pathway altogether.

Maintaining the result: the long-term monitoring approach

Cartilage has limited capacity to repair itself without support — once a defect has been filled with new matrix, the biological environment needs to be maintained rather than left unattended. That is the rationale for a structured long-term monitoring approach rather than treating a single injection as a definitive end-point.

One way this is implemented in specialist practice combines periodic ChondroFiller top-up injections approximately every two years, annual peptide support to maintain the biochemical environment, and regular MRI review to assess tissue fill quality structurally. MRI monitoring provides a MOCART-based measure of how well the scaffold has integrated and whether the regenerated tissue is holding — a structural assessment that runs alongside, rather than being replaced by, patient-reported symptom improvement.

It is worth being clear that this is a clinically guided framework rather than a protocol independently validated in a long-term comparative trial. The strongest available longitudinal anchor is durability data showing maintained outcomes at five years and beyond in suitable patients. That evidence supports the long-term framing without constituting a formal arthroplasty-avoidance study — a distinction worth acknowledging once, before recognising that proactive monitoring of a regenerative scaffold is, at minimum, biologically coherent.

Getting assessed at the London Cartilage Clinic

A specialist assessment for ChondroFiller injection in the hip typically begins with MRI review — confirming defect grade, lesion size, and the quality of surrounding cartilage before any treatment decision is reached. Suitability is not assumed from symptoms alone; the structural picture determines whether the scaffold has a viable environment in which to work, and whether the injectable route is appropriate or whether a surgical restoration procedure would serve better.

In the UK, ChondroFiller injection is available at the London Cartilage Clinic on Harley Street. The programme is led by Professor Paul Y. F. Lee, whose experience with image-guided placement reflects the technique-sensitive nature of injectable scaffold procedures — the same product can produce different results depending on how and where it is delivered.

The pathway is self-funded. A single-box injection, appropriate for most focal hip defects, is priced at approximately £3,000, inclusive of consultation, ultrasound guidance, and follow-up review. Patients can explore suitability and arrange a consultation at londoncartilage.com.

1. [1] Femoroacetabular impingement. https://en.wikipedia.org/?curid=20754811 https://en.wikipedia.org/?curid=20754811
2. [2] Articular cartilage repair. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351